News | Astellas Pharma Inc.
WEBAstellas Receives Approval from the European Commission for VYLOY TM (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
Newsroom | Astellas Pharma Inc.
WEBSep 24, 2024 · Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024. Sep 05, 2024 Press Releases. Astellas to Present VEOZAH TM (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society. EXPLORE ALL …
Astellas Pharma US, Inc. | News Room - News Releases
WEBSep 20, 2024. Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer. Read More. News / Media. Sep 18, 2024. Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure. Read More. News / Media. Sep 11, 2024.
Astellas Enters into Definitive Agreement to Acquire Iveric Bio
WEBApr 30, 2023 · Astellas aims to become a cutting-edge, VALUE-driven life science innovator to realize its VISION to be "on the forefront of healthcare change to turn innovative science into...
Astellas and Kelonia Therapeutics Enter into Research and License ...
WEBTOKYO and BOSTON, Feb. 15, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Kelonia Therapeutics (CEO, Founder: Kevin Friedman, Ph.D.,...
Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational ...
WEBApr 14, 2023 · The primary endpoint is progression-free survival of participants treated with combination of zolbetuximab plus CAPOX compared to those treated with placebo plus CAPOX. Secondary endpoints include...
News | Astellas Pharma Inc.
WEBMar 4, 2024 · News from Astellas. Latest and past news available. TOKYO, March 4, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced dosing of the first patient in the STARLIGHT™ 2 Phase 3 pivotal study for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of ...
News - Astellas Pharma Inc. - Astellas Gene Therapies
WEBAstellas Completes Acquisition of Audentes Therapeutics. Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas’ newly created Genetic Regulation Primary Focus.
Astellas Unveils New, State-of-the-Art, $90 Million West
WEBTOKYO and SAN FRANCISCO, May 8, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the opening of a new $90 million, state-of-the-art center at 480 Forbes Boulevard in South San Francisco, CA. The newly built 154,000-square-foot lab and office facility expands the company’s ...
Astellas switches CEOs amid plans to pursue ‘aggressive’ growth
WEBFeb 6, 2023 · Five years into a strategic reboot, Japanese drugmaker Astellas Pharma plans to switch CEOs and “go on the aggressive” to accelerate growth. Along with a quarterly earnings statement Monday, Astellas revealed that its current CEO, Kenji Yasukawa, will step down in April and be replaced by …